×
News Home

Is NovaBay Pharmaceuticals, Inc. (NBY) Stock at the Top of the Biotechnology Industry?

Friday, November 26, 2021 09:58 AM | InvestorsObserver Analysts
Is NovaBay Pharmaceuticals, Inc. (NBY) Stock at the Top of the Biotechnology Industry?

NovaBay Pharmaceuticals, Inc. (NBY) is around the top of the Biotechnology industry according to InvestorsObserver. NBY received an overall rating of 51, which means that it scores higher than 51 percent of all stocks. NovaBay Pharmaceuticals, Inc. also achieved a score of 77 in the Biotechnology industry, putting it above 77 percent of Biotechnology stocks. Biotechnology is ranked 89 out of the 148 industries.

Overall Score - 51
NBY has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on NBY!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 51 would rank higher than 51 percent of all stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With NovaBay Pharmaceuticals, Inc. Stock Today?

NovaBay Pharmaceuticals, Inc. (NBY) stock is up 12.15% while the S&P 500 has fallen -1.7% as of 9:57 AM on Friday, Nov 26. NBY is up $0.06 from the previous closing price of $0.48 on volume of 1,284,882 shares. Over the past year the S&P 500 is up 27.02% while NBY has fallen -15.63%. NBY lost -$0.17 per share the over the last 12 months. Click Here to get the full Stock Report for NovaBay Pharmaceuticals, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App